OrbiMed, BDC raise Clementia Pharmaceuticals' Series A to $32.5 mln
Clementia Pharmaceuticals Inc has raised a $10 million top up to its Series A financing round, which was announced in January 2014. As a result, the round now totals $32.5 million. U.S. venture capital firm OrbiMed Advisors led the deal with the participation of BDC Capital Healthcare Venture Fund, a fund managed by Canadian firm BDC Capital. Based in Dorval, Québec, Clementia is a clinical-stage biopharmaceutical company focused on developing innovative therapies for people living with rare diseases, including bone disease. It also announced that is has formed Clementia Pharmaceuticals USA Inc to manage the company's operations in the United States.
5 January 2015•3 mins read
